FDA Letter API

Sperm Bank, Inc. dba Fertility Center of California

Letter data

Company
Sperm Bank, Inc. dba Fertility Center of California
Recipient
Martin D. Bastuba, M.D. | Owner/Medical Director | Sperm Bank, Inc. dba Fertility Center of California | 6699 Alvarado Road, Suite 2208 | San Diego | , | CA | 92120 | United States | Director@fertilityCTR.com
Issue date
2026-02-09
Posted date
Not available
FDA office
Center for Biologics Evaluation and Research (CBER)
Subject
Not available
Product
Biologics
CMS ID
694273
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Sperm Bank, Inc. dba Fertility Center of California MARCS-CMS 694273 — February 09, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Product: Biologics Recipient: Recipient Name Martin D. Bastuba, M.D. Recipient Title Owner/Medical Director Sperm Bank, Inc. dba Fertility Center of California 6699 Alvarado Road, Suite 2208 San Diego , CA 92120 United States Director@fertilityCTR.com Issuing Office: Center for Biologics Evaluation and Research (CBER) United States Secondary Issuing Offices United States Dear Dr. Bastuba: The Food and Drug Administration has completed evaluation of your corrective actions in response to our Warning Letter CBER 25-694273 dated February 14, 2025. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Act(s) and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Melissa J. Mendoza Director Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research Content current as of: 02/19/2026 Regulated Product(s) Biologics